Posted by Michael Wonder on 15 Sep 2023
Dizal announces China CDE acceptance of new drug application for golidocitinib for relapsed or refractory PTCL
14 September 2023 - Dizal today announced that the Center for Drug Evaluation of the China NMPA has accepted the new drug application for golidocitinib for the treatment of relapsed or refractory peripheral T-cell lymphoma.
The new drug application submission for golidocitinib is supported by data from the JACKPOT8 PARTB study, a multinational, pivotal study to evaluate the efficacy and safety of golidocitinib in patients with relapsed or refractory peripheral T-cell lymphoma.
